Kadmos Capital
Edit

Kadmos Capital

https://kadmoscapital.com/
Last activity: 14.09.2026
Active
In an increasingly unstable world, we are inspired by those who are seeking solutions to humanity’s most pressing problems.
Portfolio
6
Mentions
25
Investment Stage: Seed

Portfolio 6

DateNameWebsiteTotal RaisedLocation
27.08.2026Stability ...stability.ai$656MUnited Sta...
13.01.2026OutSeeoutsee.co.uk$5.82MUnited Kin...
23.09.2025Scindoscindo.bio$5.4MUnited Kin...
15.07.2025Aeonaeon.life$9.51MGermany
19.02.2024GlycanAgeglycanage.com$13.1MCroatia
02.06.2023XONAIxonai.io$3.5MUnited Kin...

Mentions in press and media 25

DateTitleDescription
14.09.2026Following a seed extension, AEON acquires consumer blood diagnostics platform Whole-body MRI is powerful but episodic. Blood testing is recurring. With the acquisition of Aware Health’s assets, Aeon is now the first European platform to offer a continuous, longitudinal health picture, updated quarter after quarter. ...
27.08.2026Stability AI Raises $76 Million Series B With EA, Sony, UMG And Warner Music BackingStability AI has raised $76 million in Series B funding, bringing the generative AI company’s total financing under CEO Prem Akkaraju to $232 million across two equity rounds and convertible notes. The financing brings together a notable gr...
25.08.2026The Entertainment Industry's Biggest Names Back Stability AI in Latest Funding RoundTotal funding reaches $232M under new leadership with investor group comprised of Electronic Arts, Sony Music Group, Universal Music Group, Warner Music Group, and more LOS ANGELES, Aug. 25, 2026 /PRNewswire/ -- Stability AI, the leader in ...
03.03.2026Antiverse: $9.3 Million Raised For AI-Driven Antibody Development Targeting Undruggable Disease TargetsAntiverse, an AI-driven techbio company specializing in de novo antibody design for challenging drug targets, has raised $9.3 million in Series A financing to accelerate the development of therapeutic antibodies aimed at historically undrug...
27.01.2026GlycanAge Raises EUR 7.4M to Turn Aging Into Data and Detect Risk Before DiseaseBritish startup GlycanAge with Croatian founders translates glycan science into clinically actionable biological aging diagnostics The company focuses on early risk detection through stable, inflammation-linked IgG glycan biomarkers The com...
14.01.2026OutSee Secures £2.5M, Propels AI Genomics for Drug DiscoveryOutSee secured a significant £2.5M seed funding round. Ahren Innovation Capital spearheaded the investment. This capital fuels OutSee's groundbreaking AI-powered Nomaly platform. Nomaly uses a "genomics-first" approach. It predict...
13.01.2026OutSee Closes £2.5M Seed Funding RoundOutSee, a Cambridge, England-based developer of an AI-based predictive genomics approach to target discovery, raised £2.5M in seed funding. The round was led by Ahren Innovation Capital, with participation from Kadmos Capital, Panacea, Empi...
12.01.2026OutSee: £2.5 Million Seed Round Completed And Partnership With o2h DiscoveryOutSee, an AI-enabled genomics and drug discovery company, has closed a £2.5 million seed funding round and signed a strategic agreement with o2h discovery to begin a collaborative drug discovery programme around OutSee’s lead drug target c...
19.12.2025GlycanAge Secures Major Funding. Reshaping Healthcare with Biological Age Diagnostics.GlycanAge, a UK biotech rooted in Croatian research, just secured €7.4 million. This significant investment propels glycan-based aging diagnostics into mainstream healthcare. Their "inflammaging" clock, a cutting-edge biomarker, p...
18.12.2025GlycanAge Founders on Boosting Transition From “Wellness” Biomarker to Hospital DiagnosticCroatia, UK ~ Company: Glycans, sugar molecules that shape immune response, inflammation and ageing, are well studied in research labs but rarely used in everyday clinical diagnostics. Croatian-founded GlycanAge, a London-headquartered biot...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In